Ascletis Pharma Inc. 2VJ.F Stock
Ascletis Pharma Inc. Price Chart
Ascletis Pharma Inc. 2VJ.F Financial and Trading Overview
| Ascletis Pharma Inc. stock price | 0.09 EUR |
| Previous Close | 0.22 EUR |
| Open | 0.23 EUR |
| Bid | 0.21 EUR x 0 |
| Ask | 0.24 EUR x 0 |
| Day's Range | 0.23 - 0.23 EUR |
| 52 Week Range | 0.21 - 0.62 EUR |
| Volume | 3K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 246.96M EUR |
| Beta (5Y Monthly) | 0.89211 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
2VJ.F Valuation Measures
| Enterprise Value | -2236926976 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.5657935 |
| Price/Book (mrq) | 0.09674657 |
| Enterprise Value/Revenue | -41.356 |
| Enterprise Value/EBITDA | 6.936 |
Trading Information
Ascletis Pharma Inc. Stock Price History
| Beta (5Y Monthly) | 0.89211 |
| 52-Week Change | -52.96% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.62 EUR |
| 52 Week Low | 0.21 EUR |
| 50-Day Moving Average | 0.27 EUR |
| 200-Day Moving Average | 0.37 EUR |
2VJ.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 1.09B |
| Float | 254.48M |
| Short Ratio | N/A |
| % Held by Insiders | 67.02% |
| % Held by Institutions | 2.24% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -644.51% |
| Gross Margin | -45.65% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -7.94% |
| Return on Equity (ttm) | -11.95% |
Income Statement
| Revenue (ttm) | 54.09M EUR |
| Revenue Per Share (ttm) | 0.05 EUR |
| Quarterly Revenue Growth (yoy) | -60.60% |
| Gross Profit (ttm) | -24692000 EUR |
| EBITDA | -322487008 EUR |
| Net Income Avi to Common (ttm) | -314843008 EUR |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.48B EUR |
| Total Cash Per Share (mrq) | 2.29 EUR |
| Total Debt (mrq) | 4.24M EUR |
| Total Debt/Equity (mrq) | 0.17 EUR |
| Current Ratio (mrq) | 23.521 |
| Book Value Per Share (mrq) | 2.336 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -142452992 EUR |
| Levered Free Cash Flow (ttm) | -114006752 EUR |
Profile of Ascletis Pharma Inc.
| Country | Germany |
| State | N/A |
| City | Hangzhou |
| Address | Building D |
| ZIP | N/A |
| Phone | 86 571 8538 9730 |
| Website | https://www.ascletis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 278 |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Q&A For Ascletis Pharma Inc. Stock
What is a current 2VJ.F stock price?
Ascletis Pharma Inc. 2VJ.F stock price today per share is 0.09 EUR.
How to purchase Ascletis Pharma Inc. stock?
You can buy 2VJ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ascletis Pharma Inc.?
The stock symbol or ticker of Ascletis Pharma Inc. is 2VJ.F.
Which industry does the Ascletis Pharma Inc. company belong to?
The Ascletis Pharma Inc. industry is Biotechnology.
How many shares does Ascletis Pharma Inc. have in circulation?
The max supply of Ascletis Pharma Inc. shares is 1.14B.
What is Ascletis Pharma Inc. Price to Earnings Ratio (PE Ratio)?
Ascletis Pharma Inc. PE Ratio is now.
What was Ascletis Pharma Inc. earnings per share over the trailing 12 months (TTM)?
Ascletis Pharma Inc. EPS is -0.02 EUR over the trailing 12 months.
Which sector does the Ascletis Pharma Inc. company belong to?
The Ascletis Pharma Inc. sector is Healthcare.